Company intelligence / Profile preview
D3 Bio
Wuxi, Jiangsu, Chinad3bio.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
D3S-001, their lead KRAS G12C inhibitor, is currently in phase II development for non-small cell lung cancer, colorectal cancer, and pancreatic cancer. Recent studies show it has significantly improved covalent potency and better target engagement kinetics compared to approved drugs in its class (sotorasib and adagrasib)[4][5].
- Therapeutic areas
- Oncology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →03
Partnerships
Medicxi
Beyond the preview
Go deeper on D3 Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on D3 Bio.